Curapath

What Curapath does

Curapath (legal entity: Polypeptide Therapeutic Solutions S.L.) is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Paterna, Valencia, Spain, with a US commercial office in Cambridge, MA. Founded in 2013 and rebranded from PTS (Polypeptide Therapeutic Solutions) to Curapath, the company specializes in non-viral drug delivery systems based on lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), and polymer-drug conjugates, serving biotech and pharmaceutical companies developing RNA therapeutics, gene therapies, mRNA vaccines, and advanced biologics. Its proprietary technology stack includes STAR-CXP polyaminoacid transfection polymers (reportedly delivering up to 9x higher transfection efficiency than jetPEI) and Polysarcosine (PSar), a PEG-free stealth shielding polymer positioned as a lower-immunogenicity alternative to PEGylation.

The company offers end-to-end CDMO services spanning pre-clinical process development, GMP clinical supply manufacturing, and commercial-scale production, backed by AEMPS Authorization Number 6754E for manufacturing investigational medicinal products and a track record of 250+ GMP batches released with 100% compliance. Curapath monetizes through two streams: (1) professional services CDMO contracts with phase-appropriate pricing from preclinical through commercial GMP production, and (2) a product catalog selling proprietary and reference polymer/lipid excipients, ionizable lipids, shielding lipids, and nanoparticle components for research and GMP use. Go-to-market is B2B enterprise field sales supported by technical subject matter experts, with customer acquisition driven by industry events (ASCGT, TIDES USA), a technical resource library, the NanoTalks blog, and direct relationship management. The company reports an NPS of 61 measured by Hubspot in 2024, with customer testimonials concentrated among startup and mid-sized biotech clients including Elastrin Therapeutics, GenEdit, Iris Biotech, Macro Biologics, BioDevek, KNAUER, SYNGOI, and Orphatrade.

Curapath operates in markets projected at $5.8B (pharmaceutical lipids, 2026, growing at 5.0% CAGR to $9.4B by 2036) and $420.2B (nanobiotechnology by 2034, 9.37% CAGR). Leadership is headed by CEO Philippe Clavel, with Juan José Arroyo serving as Head of Project Management Office. The company has no disclosed funding rounds, no M&A activity, and no identified institutional investors in the source data.

Name

Curapath

Legal name

Polypeptide Therapeutic Solutions S.L.

Website

https://curapath.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

Curapath is a Spain-based CDMO specializing in non-viral drug delivery systems, including lipid nanoparticles, polymer nanoparticles, and polymer-drug conjugates. It serves biotech and pharma companies developing RNA therapeutics, gene therapies, and advanced biologics from preclinical through commercial GMP manufacturing.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Nanotechnology (541713)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

akta.pro secondary industries

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)

Keywords

• Contract pharmaceutical manufacturing
• Lipid nanoparticles
• Polymer nanoparticles
• Non-viral drug delivery
• GMP manufacturing services

Headquarters

HQ city

Paterna

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Services (Contract Manufacturing): Phase-appropriate contract development and manufacturing services from preclinical through commercial GMP production, including process development, analytical methods, formulation, and batch certification for polymer and lipid-based drug delivery systems.
2. Product Catalog (Excipients and Reagents): Sale of proprietary and reference polymer and lipid excipients, ionizable lipids, shielding lipids, polymers, and nanoparticle components for research, preclinical, and GMP applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Curapath is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for polymer and lipid-based non-viral drug delivery systems. The company offers preclinical development through commercial-scale GMP manufacturing of lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer-drug conjugates, and functional excipients. It also sells a proprietary catalog of ionizable lipids, shielding polymers, and excipients for research and clinical applications.

Product overview

Curapath is a science-driven Contract Development and Manufacturing Organization (CDMO) specializing in polymer and lipid-based non-viral drug delivery systems. The company operates as an integrated platform with two core delivery technologies—Lipid Nanoparticles (LNPs) and Polymer Nanoparticles (PNPs)—complemented by extensive component portfolios including ionizable lipids, shielding lipids, ionizable cationic polymers, shielding polymers (notably Polysarcosine as a PEG-free alternative), and polymer-drug conjugates. Curapath provides end-to-end services spanning pre-clinical development (formulation screening, process development, pilot manufacturing), clinical supply (GMP production, IND/IMPD packages, batch certification), and commercial manufacturing (validation, regulatory support). The platform is supported by comprehensive analytical methods for LNP and PNP characterization. Recent innovations include STAR-CXP polyaminoacid transfection polymers, lipid-polymer hybrid nanoparticles (LPHNs), and the next-generation LNP formulation developed in partnership with Certest.

Differentiator

Problem solved

Functional benefit

Brands

• NanoTalks: Curapath's blog magazine covering latest trends and practices in non-viral vectors and nanobiotechnology.
• STAR-CXP

Products and services

• Lipid Nanoparticles (LNPs)
• Polymer Nanoparticles (PNPs)
• STAR-CXP Polyaminoacid Polymers
• Polymer-Drug Conjugates
• Ionizable Lipids
• Shielding Lipids
• Ionizable Cationic Polymers
• Shielding Polymers
• Polysarcosine (PSar)
• Curapath Product Catalog
• Pre-Clinical Development Services
• Clinical Supply Services
• Commercial Manufacturing Services
• Analytical Methods Services
• LNP/PNP Formulation Services
• Bio-Conjugation Services

Quantifiable outcome

• NPS of 61 reflecting high customer satisfaction
• +2 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• CertestcoreStrategic or Co-development Partner · 17 March 2025Certest and Curapath have joined forces to develop a novel LNP formulation leveraging the complementary benefits of their proprietary excipients. This collaboration combines Certest's diagnostic and testing capabilities with Curapath's lipid nanoparticle formulation expertise for next-generation LNP development.
• University of California Los Angeles (UCLA)minorStrategic or Co-development PartnerAcademic collaboration with Professor Tim J. Deming in bioengineering, recognizing Curapath's depth of understanding and level of expertise in polypeptide manufacturing and analytics.
• Universitat Jaume IminorStrategic or Co-development PartnerAcademic partnership with BIOSUPRAMAT research group led by Dr. Beatriu Escuder, positioning Curapath as an ideal partner for transferring fundamental research into market applications.

Scale indicators4 records

Expansion highlights6 records

Direct peers

• Acuitas Therapeutics: Acuitas is a specialist LNP technology company providing ionizable lipid and LNP formulation development, with deep partnerships in mRNA vaccine and therapeutic delivery. It is the closest direct comparable to Curapath's LNP formulation and manufacturing business.
• Genevant Sciences: Genevant develops lipid nanoparticle delivery systems for RNA therapeutics and has commercial LNP partnerships across the industry. It competes head-to-head with Curapath in non-viral nucleic acid delivery CDMO services.
• Polypeptide Group: Polypeptide Group is a specialized CDMO focused on peptide and polypeptide API manufacturing. It shares Curapath's heritage (Curapath was formerly PTS Polypeptide Therapeutic Solutions) and operates in adjacent polymer/peptide drug delivery manufacturing.

Broad incumbents

• CordenPharma: CordenPharma is a global CDMO with established lipid and peptide manufacturing capabilities, including LNP formulation services. It is a broader incumbent competitor with deeper resources and a wider service portfolio.
• Evonik (Health Care): Evonik operates a CDMO business that includes lipid excipients and polymer-based drug delivery systems. It is a diversified chemical and CDMO incumbent with overlapping capabilities in functional excipients and nanoparticle formulation.
• BioNTech (Polymun Scientific): BioNTech operates in-house LNP manufacturing capabilities (via its Polymun Scientific acquisition) for mRNA therapeutics. It is a broad incumbent that both competes with and represents the kind of internal capacity that Curapath's clients may opt to build.
• PCI Pharma Services: PCI Pharma Services is a global CDMO offering injectable and complex formulation manufacturing, with growing capabilities in lipid-based drug delivery. It is a broader incumbent alternative for biotech clients evaluating CDMO partners.

Emerging players

• Vernal Biosciences: Vernal Biosciences is an emerging CDMO specializing in mRNA and LNP formulation services for clinical-stage developers. It is comparable to Curapath as a smaller specialist targeting the same LNP manufacturing niche.
• Ascendia Pharma: Ascendia Pharma is a specialty CDMO providing formulation development and manufacturing for poorly soluble and complex drug products, including nanoemulsions and lipid-based systems. It is an emerging player with comparable complex formulation capabilities.

Others

• Tune Therapeutics: Tune Therapeutics is a developer of epigenetic gene-editing therapeutics using non-viral delivery. While not a CDMO, it is a representative buyer of specialized non-viral delivery CDMO services and a relevant ecosystem comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/curapath

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curapath